Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:2075-2081
doi: 10.1161/hc4201.097187
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, Q. T.
Right arrow Articles by Rouleau, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, Q. T.
Right arrow Articles by Rouleau, J. L.
Related Collections
Right arrow Congestive
Right arrow Remodeling
Right arrow Acute myocardial infarction

(Circulation. 2001;104:2075.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Long-Term Effects of Nonselective Endothelin A and B Receptor Antagonism in Postinfarction Rat

Importance of Timing

Quang Trinh Nguyen, MSc; Peter Cernacek, MD PhD; Martin G. Sirois, PhD; Angelino Calderone, PhD; Nathalie Lapointe, MSc; Duncan J. Stewart, MD; Jean L. Rouleau, MD

From the Department of Medicine, Montreal Heart Institute, Montreal, Quebec (Q.T.N., P.C., M.G.S., A.C.), and the Division of Cardiology (N.L., J.L.R.) and the Terrance Donnelly Heart Center, St Michael’s Hospital (D.J.S.), University of Toronto, Toronto, Ontario, Canada.

Correspondence to Dr Jean L. Rouleau, Division of Cardiology, Toronto General Hospital, Eaton North 13-212, 200 Elizabeth St, Toronto, ON, Canada, M5G 2C4. E-mail jean.rouleau{at}uhn.on.ca

Background— Some controversy exists as to the effects of endothelin (ET) receptor antagonism on long-term post–myocardial infarction (MI) evolution, particularly as it relates to the timing of the intervention after MI (<24 hours versus 10 days).

Methods and Results— Sham rats and rats surviving an acute MI for >20 hours (n=301) were assigned to treatment with saline or the nonselective ETA and ETB receptor antagonist LU 420627 (LU) started <24 hours (early) or 10 days (late) after MI and continued for 100 days. Long-term LU treatment led to increased mortality of rats with large MI, regardless of the timing of initiation of therapy. Early initiation of LU reduced survival from 61% to 16% (P<0.001 versus untreated), and later initiation reduced survival to 36% (P=0.012 versus untreated and P<0.001 versus early initiation). Early initiation of LU led to scar thinning, further left ventricular (LV) dilatation, LV dysfunction, and an excessive rise in right ventricular systolic pressure. Later initiation of LU did not modify scar formation but resulted in LV dilatation and dysfunction compared with the untreated group. Cardiac fibrosis tended to increase in the LU-treated MI groups. LU in the sham group reduced cardiac endothelial constitutive nitric oxide synthase but did not modify the changes that occurred with a large MI.

Conclusions— The use of the nonselective ETA and ETB receptor antagonist LU results in reduced survival, ventricular dilatation, and dysfunction whether started early or late after MI. Early initiation of LU resulted in scar expansion and a particularly unfavorable outcome.


Key Words: myocardial infarction • survival • endothelium-derived factors • remodeling




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
N. F. Kelland and D. J. Webb
Clinical Trials of Endothelin Antagonists in Heart Failure: A Question of Dose?
Experimental Biology and Medicine, June 1, 2006; 231(6): 696 - 699.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
V. Chintalgattu and L. C. Katwa
Role of Protein Kinase C{delta} in Endothelin-Induced Type I Collagen Expression in Cardiac Myofibroblasts Isolated from the Site of Myocardial Infarction
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 691 - 699.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. L. Yang, R. Gros, M. G. Kabir, A. Sadi, A. I. Gotlieb, M. Husain, and D. J. Stewart
Conditional Cardiac Overexpression of Endothelin-1 Induces Inflammation and Dilated Cardiomyopathy in Mice
Circulation, January 20, 2004; 109(2): 255 - 261.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Mulder, H. Boujedaini, V. Richard, J.-P. Henry, S. Renet, K. Munter, and C. Thuillez
Long-Term Survival and Hemodynamics After Endothelin-A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition in Rats With Chronic Heart Failure: Monotherapy Versus Combination Therapy
Circulation, August 27, 2002; 106(9): 1159 - 1164.
[Abstract] [Full Text] [PDF]